Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CEA Acquisition Corporation and etrials Worldwide Announce Filing of Amended Form S-4 Registration Statement.


TAMPA, Fla. & MORRISVILLE Morrisville, borough (1990 pop. 9,765), Bucks co., SE Pa., on the Delaware River opposite Trenton, N.J.; settled c.1624 by the Dutch West India Company, inc. 1804. Water pumps, clutches, coatings, and concrete and rubber products are among the manufactures. , N.C. -- CEA CEA carcinoembryonic antigen.

CEA
abbr.
carcinoembryonic antigen


CEA (Carcinoembryonic antigen) 
 Acquisition Corporation (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
: CEAC CEAC Chemical Engineering and Applied Chemistry
CEAC Conférence Européenne de l'Aviation Civile (French: European Civil Aviation Conference)
CEAC Compensatory Education Advisory Committee
, CEACU, CEACW) ("CEAC"), a special purpose acquisition company, and privately held etrials Worldwide, Inc. ("etrials"), a global provider of integrated software Separate software components or applications that have been combined into one package. See integrated software package.  for the life sciences industry, announced today that CEAC had filed an amended a·mend  
v. a·mend·ed, a·mend·ing, a·mends

v.tr.
1. To change for the better; improve: amended the earlier proposal so as to make it more comprehensive.

2.
 registration statement on Form S-4 with the Securities and Exchange Commission on December 13, 2005. The Form S-4 includes, among other information, unaudited financial information for etrials as of and for the nine months ended September 30, 2005. As previously announced, CEAC and etrials have entered into a definitive merger agreement pursuant to which etrials will become a wholly owned subsidiary Wholly Owned Subsidiary

A subsidiary whose parent company owns 100% of its common stock.

Notes:
In other words, the parent company owns the company outright and there are no minority owners.
 of CEAC.

Unaudited Financial Information

etrials' backlog Backlog

The total value of sales orders waiting to be fulfilled.

Notes:
This figure is used mainly in the manufacturing industry. Increases or decreases in a company's backlog indicate the future direction of sales and earnings.
 increased 43% to $22.3 million at September 30, 2005 from $15.6 million at September 30, 2004. etrials' backlog at October 31, 2005 was $24.3 million, as compared with backlog of $20.4 million at December 31, 2004. Backlog is defined as the remaining value of contracts and written commitments clients have awarded to etrials. All client contracts are subject to possible delays, cancellation or changes in scope which can impact backlog. Accordingly, current backlog is not necessarily indicative of etrials' future quarterly or annual revenue.

For nine months ended September 30, 2005, etrials' revenue increased 24.4% to approximately $10.8 million from approximately $8.7 million in the comparable prior year period. This reflects an increase in the number of contracts in backlog as of September 30, 2005, which itself reflects an increase in the market penetration Noun 1. market penetration - the extent to which a product is recognized and bought by customers in a particular market
penetration - the act of entering into or through something; "the penetration of upper management by women"
 of etrials' eClinical software suite of products and a rising industry adoption rate of eClinical technologies.

During the nine months ended September 30, 2005, etrials recorded a $396,666 discount to revenues (versus no such reduction in the comparable 2004 period) in connection with a software application-hosting agreement entered into on April 1, 2005. This reduction in revenue was made pursuant to EITF EITF Emerging Issues Task Force
EITF Edinburgh International Television Festival
EITF Europe International Taekwon-Do Federation
 01-9, Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller An organization that sells hardware and software to the general public. Resellers purchase products from software publishers and hardware manufacturers.  of the Vendor's Products), which is discussed in more detail in Amendment No. 1 to the Form S-4 as filed with the SEC on December 13, 2005.

Cost of revenues increased to approximately $4.9 million, or 45.3% of revenues, from approximately $3.4 million, or 39.3% of revenues, in the same period last year. In addition to higher personnel and related costs associated with an increase in etrials' services staff, cost of revenues for the 2005 nine-month period included:

--approximately $279,000 in settlement costs related to the August 2005 patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver.  litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
 settlement ("the patent litigation");

--approximately $229,000 of increased expenses related to amortization of capitalized Capitalized

Recorded in asset accounts and then depreciated or amortized, as is appropriate for expenditures for items with useful lives longer than one year.
 internal software development costs, software licenses In computing, software that is copyrighted and licensed under a software license is done under a variety of licensing schemes. For end-users there are proprietary licenses and there are free software licenses, and there are proprietary Within these schemes are further classifications.  and royalties; and

--approximately $129,000 of increased client pass through costs.

General and administrative costs administrative costs,
n.pl the overhead expenses incurred in the operation of a dental benefits program, excluding costs of dental services provided.
 as a percentage of revenues rose slightly to 21.9% from 21.6% in the same period one year ago. General and administrative costs for the 2005 nine-month period included $411,000 in legal expenses associated with the patent litigation, versus no such expenses in the comparable period of 2004.

The net loss for the first nine months of 2005 was approximately $151,000 as compared to net income of approximately $156,300 in the first nine months of 2004. The net loss for the 2005 period was negatively impacted by the patent litigation and settlement costs of approximately of $690,000, as well as the $396,666 revenue reduction related to the prepaid pre·pay  
tr.v. pre·paid, pre·pay·ing, pre·pays
To pay or pay for beforehand.



pre·payment n.
 software application-hosting discount.

As of September 30, 2005, etrials' total assets were approximately $14.6 million, current assets Current Assets

Appearing on a company's balance sheet, it represents cash, accounts receivable, inventory, marketable securities, prepaid expenses, and other assets that can be converted to cash within one year.
 were approximately $4.9 million, and working capital was approximately $1.2 million. Also as of September 30, 2005, etrials had approximately $636,000 in short-term debt Short-term debt

Debt obligations, recorded as current liabilities, requiring payment within the year.
 and $170,000 in long-term debt Long-Term Debt

Loans and financial obligations lasting over one year.

Notes:
For example debts obligations such as bonds and notes which have maturities greater than one year would be considered long-term debt.
.

The audited and unaudited financial statements of CEAC can be found on the Securities and Exchange Commission Web site (http://www.sec.gov) within CEAC's 10-KSB and 10-QSB filings for the relevant periods. As of September 30, 2005, CEAC had total and current assets of approximately $21.5 million, principally comprised of cash, and no debt.

Forward-Looking Statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995, about CEAC, etrials and their combined business after completion of the proposed merger. Forward- looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of CEAC's and etrials' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: Business conditions in the U.S. and abroad; changing interpretations of generally accepted accounting principles The standard accounting rules, regulations, and procedures used by companies in maintaining their financial records.

Generally accepted accounting principles (GAAP) provide companies and accountants with a consistent set of guidelines that cover both broad accounting
; outcomes of government reviews; inquiries and investigations and related litigation; continued compliance with government regulations; legislation or regulatory environments, requirements or changes adversely affecting the businesses in which etrials is engaged; fluctuations in customer demand; management of rapid growth; intensity of competition; general economic conditions; as well as other relevant risks detailed in CEAC's filings with the Securities and Exchange Commission, including its report on Form 10-QSB for the period ended September 30, 2005 and Registration Statement on Form S-4. The information set forth herein should be read in light of such risks. Neither CEAC nor etrials assumes any obligation to update the information contained in this press release.

Additional Information

CEAC stockholders are urged to read the definitive proxy statement Proxy Statement

A document containing the information that a company is required by the SEC to provide to shareholders so they can make informed decisions about matters that will be brought up at an annual stockholder meeting.
 regarding the proposed transaction when it becomes available because it will contain important information. Copies of filings by CEAC, which will contain information about CEAC and etrials, will be available without charge, when filed, at the Securities and Exchange Commission's internet site (http://www.sec.gov) and, when filed, will be available from CEAC, without charge, by directing a request to CEAC Acquisition Corporation, 101 East Kennedy Boulevard, Suite 3300, Tampa, FL 33602.
etrials WORLDWIDE, INC.
                 CONDENSED CONSOLIDATED BALANCE SHEETS


                                    9/30/2005  12/31/2004  12/31/2003
                                    ---------  ----------  ----------
                                   (unaudited)
Assets
   Cash and cash equivalents       $1,440,494  $1,706,649  $1,529,822
   Other current assets             3,447,509   2,735,716   1,733,593
                                  ------------------------------------
Total current assets                4,888,003   4,442,365   3,263,415

Property and equipment,
 net of depreciation                1,041,533     875,673   1,011,118
Other assets                        8,715,015   8,781,460   9,181,410
                                  ------------------------------------
Total assets                      $14,644,551 $14,099,498 $13,455,943
                                  ====================================

Liabilities, redeemable
 convertible preferred stock
 and stockholders' deficit
   Current liabilities             $3,676,494  $3,499,728  $5,010,795
   Long-term liabilities              253,039      40,000      85,000
                                  ------------------------------------
Total liabilities                   3,929,533   3,539,728   5,095,795

Series A & B redeemable
 convertible preferred stock       13,359,066  12,494,445   9,854,365

Stockholders' deficit              (2,644,048) (1,934,675) (1,494,217)
                                  ------------------------------------
Total liabilities, redeemable
 convertible preferred stock
 and stockholders' deficit        $14,644,551 $14,099,498 $13,455,943
                                  ====================================



                        etrials WORLDWIDE, INC.
            CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


                 Nine Months Ended
                   September 30           Years Ended December 31
              ---------------------- ---------------------------------
                  2005       2004        2004       2003       2002
              ----------- ---------- ----------- ---------- ----------
                    (Unaudited)

Revenues      $10,816,528 $8,693,214 $12,766,306 $7,917,855 $4,601,615

Costs and
 expenses:
Costs of
 revenues       4,895,609  3,415,469   5,243,597  3,822,404  3,542,027
Sales and
 marketing      2,160,629  1,625,843   2,350,369  1,743,510  1,530,741
General and
 administrative 2,372,980  1,875,203   2,739,204  2,491,192  1,401,648
Amortization of
 intangible
 assets           419,617    401,024     539,513    471,071    906,025
Research and
 development    1,129,990    972,890   1,341,350  1,438,623    955,422
              ----------- ---------- ----------- ---------- ----------

Total cost and
 expenses      10,978,825  8,290,429  12,214,033  9,966,800  8,335,863
              ----------- ---------- ----------- ---------- ----------

Operating
 (loss) income  (162,297)    402,785    552,273 (2,048,945)(3,734,248)

Other expenses
 (income):
Interest
 expense           38,216    264,237     327,085    541,080    735,286
Loss on
 extinguishment
 and conversion
 of debt, net          --         --          --    266,374         --
Interest income   (8,448)    (3,222)     (6,256)    (1,208)      (116)
Other (income)
 expense         (41,108)   (14,542)    (28,992)     12,916      2,224
              ----------- ---------- ----------- ---------- ----------

Total other
 (income)
 expenses        (11,340)    246,473     291,837    819,162    737,394
              ----------- ---------- ----------- ---------- ----------

Net (loss)
 income        $(150,957)  $156,312  $260,436 $(2,868,107)$(4,471,642)
              ----------- ---------- ----------- ---------- ----------
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 15, 2005
Words:1399
Previous Article:ASC X12 Releases First Set of W3C-Compliant XML Schemas Based on CICA.
Next Article:Modine Promotes Margaret Kelsey to Corporate Treasurer.
Topics:



Related Articles
QuadraMed Corporation Acquires CodeMaster Corporation; New Customer Base Approaches 4,000, Dominance Established in Health Information Management.
Talk Visual Registration Statement Becomes Effective.
CEA Acquisition Corporation and etrials Worldwide, Inc. Amend Merger Agreement.
Secure Computing and CyberGuard Form S-4 Registration Statement Declared Effective; Stockholders Meetings Set for January 11, 2006.
Public Sales of CEA - etrials Merger Shares to Be Restricted for 180 Days.
CEA Acquisition Corporation Schedules Special Meeting of Stockholders.
Shareholders Approve Merger between CEA Acquisition Corporation and etrials Worldwide, Inc.
etrials Continues New Product Innovation and Integration With eDiary 4.0; Enables Sponsors to Cut Costs Through Software and Device Flexibility When...
Top Global Pharmaceutical Company Successfully Deploys Largest Wireless Studies Enabled by etrials' Integrated eClinical Suite.
etrials Collaborates with Microsoft to Offer Software Solutions That Provide Enhanced Global Reach for Conducting Clinical Trials.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles